Revenue ($USD): $913,862,000
R&D spend: $62,691,000.00
Employees: 2,700
Fiscal year end: 12/31/22
CEO: Vafa Jamali
The company’s refocusing effortsincluded pulling its spine business out of Chinaandlaying off 5% of the total workforce.
One of the bright spots in the company’s spine portfolio is the ZimVie Tether,described as a groundbreaking system for treating adolescent idiopathic scoliosis.
CEO Vafa Jamali noted in ZimVie’s recent Q2 earnings call that the company has now completed all transitional service agreements related to the separation from its former parent, Zimmer Biomet.–CN